You are here

Allergan

Sandoz to pay Allergan, Duke University $39M over eye drug lawsuit, jury says

Sandoz to pay Allergan, Duke University $39M over eye drug lawsuit, jury says

Endpoints

Duke University

Flag link:

Allergan’s DREAM initiative partners with Shutterstock to promote racial equity in aesthetics

Allergan’s DREAM initiative partners with Shutterstock to promote racial equity in aesthetics

Medical Marketing and Media

pharma marketing

DREAM initiative

Flag link:

Teva, AbbVie's Allergan lock in $6.6B deal to settle thousands of US opioid lawsuits

Teva, AbbVie's Allergan lock in $6.6B deal to settle thousands of US opioid lawsuits

Fierce Pharma

Teva Pharmaceutical

Flag link:

AbbVie inks $54M settlement to resolve Namenda 'pay-for-delay' lawsuit

AbbVie inks $54M settlement to resolve Namenda 'pay-for-delay' lawsuit

Fierce Pharma

Alzheimer's disease

Flag link:

AbbVie unveils 'See Yourself' Botox campaign, days after new rival approved

AbbVie unveils 'See Yourself' Botox campaign, days after new rival approved

Endpoints

Revance Therapeutics

Flag link:

AbbVie fends off patent claim in unusual whistleblower case

AbbVie fends off patent claim in unusual whistleblower case

Fierce Pharma

whistleblower lawsuits

Alzheimer's disease

Flag link:

Teva, AbbVie ink $58M opioid settlement to resolve San Francisco claims

Teva, AbbVie ink $58M opioid settlement to resolve San Francisco claims

Fierce Pharma

Teva Pharmaceutical

Flag link:

AbbVie Inks Licensing Agreement To Use Sirona Biochem's New Skincare Technology

AbbVie Inks Licensing Agreement To Use Sirona Biochem's New Skincare Technology

CP WIre

Flag link:

AbbVie Inks Licensing Agreement To Use Sirona Biochem's New Skincare Technology

Flag link:

Teva, AbbVie's Allergan hand over $161M to settle opioid lawsuit in West Virginia

Teva, AbbVie's Allergan hand over $161M to settle opioid lawsuit in West Virginia

Fierce Pharma

Teva Pharmaceutical

Flag link:

AbbVie, Teva looking to settle nationwide opioid litigation for $5B+: Bloomberg

AbbVie, Teva looking to settle nationwide opioid litigation for $5B+: Bloomberg

Fierce Pharma

Teva Pharmaceutical

Flag link:

AbbVie's Q1 Good News That Investors Could Be Missing

AbbVie's Q1 Good News That Investors Could Be Missing

Motley Fool

Flag link:

Rhode Island reaches $28.5-million in settlements with opioid manufacturers

Rhode Island reaches $28.5-million in settlements with opioid manufacturers

The Providence Journal, RI

Teva Pharmaceutical

Flag link:

Teva, Endo and more back on the hook in San Francisco opioid trial

Teva, Endo and more back on the hook in San Francisco opioid trial

Fierce Pharma

Teva Pharmaceutical

Endo International

Flag link:

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Endpoints

major depressive disorder

Flag link:

AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger

AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger

Fierce Pharma

Flag link:

FDA restricts breast implant sales, cites Allergan and J&J for inadequate postapproval progress

FDA restricts breast implant sales, cites Allergan and J&J for inadequate postapproval progress

Medtech Dive

breast implants

Flag link:

AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug

AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug

Endpoints

Flag link:

AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next?

AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next?

Endpoints

Molecular Partners

Flag link:

Drugs facing the most patent expirations this year

Drugs facing the most patent expirations this year

Drug Patent Watch

Gilead Sciences

Flag link:

Pages